CN104740112A - Application of composition of lycopene and grape seed in preparation of drug used for treating arthritis - Google Patents
Application of composition of lycopene and grape seed in preparation of drug used for treating arthritis Download PDFInfo
- Publication number
- CN104740112A CN104740112A CN201310733246.5A CN201310733246A CN104740112A CN 104740112 A CN104740112 A CN 104740112A CN 201310733246 A CN201310733246 A CN 201310733246A CN 104740112 A CN104740112 A CN 104740112A
- Authority
- CN
- China
- Prior art keywords
- lycopene
- vitis viniferae
- semen vitis
- compositions
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses application of a composition of lycopene and grape seed in preparation of a drug used for treating arthritis. According to the invention, two components incapable of treating arthritis, i.e., the lycopene and the grape seed, are compounded according to a certain ratio, so the obtained composition has arthritis treating effect. Since the lycopene and the grape seed are natural and highly efficient active substances and pose no side-effect and irritation to the human body, the composition is safe and effective.
Description
Technical field
The present invention relates to the novelty teabag of lycopene and Semen Vitis viniferae compositions
Background technology
Arthritis is a kind of commonly encountered diseases, frequently-occurring disease of serious harm health of people, joint swelling and pain sized by clinical main manifestations, distortion, as can not symptomatic treatment in time, can cause joint tissue necrosis and quadriplegia, even lose self care ability.
At present, the arthritic medicine of western medical treatment is more, because doctor trained in Western medicine is not yet completely clear to the mechanism of this disease, great majority are based on anti-inflammatory analgesic, radical cure effect can not be played, and these medicine long-term takings are very large to the side effect of human body, after treatment, easily recurrence, brings inestimable health and menticide to patient; Though the Therapeutic Method of Chinese medicine can make stiff articular muscle be loosened, dredging the meridian, reducing swelling and alleviating pain, Chinese medicine preparation compatibility is complicated, edible inconvenient, and the poisonous pair of some Chinese medicine, stimulation; Although physical therapy and acupuncture and moxibustion therapy untoward reaction less, its late result still seldom arrives certainly.
Summary of the invention
The object of the invention is open lycopene and Semen Vitis viniferae compositions is preparing the application in medicament for treating arthritis, to overcome the defect that prior art exists, meet the needs of clinical practice.
Animal experiment proves, lycopene and Semen Vitis viniferae compositions have significant curative effect for arthritis, can be used in preparing medicament for treating arthritis;
Described lycopene and Semen Vitis viniferae compositions, the weight ratio of lycopene and Semen Vitis viniferae extract is: lycopene: Semen Vitis viniferae extract=1: 1 ~ 10;
Preferably, the weight ratio of lycopene and Semen Vitis viniferae extract is: lycopene: Semen Vitis viniferae extract=1: 2 ~ 5, most preferred, and the weight ratio of lycopene and Semen Vitis viniferae extract is: lycopene: Semen Vitis viniferae extract=1: 2 ~ 3;
Described lycopene, can adopt technology preparation disclosed in Chinese patent CN102451179A;
Described Semen Vitis viniferae extract, can adopt document: Wang Lu, Zheng Maoqiang, Wang Meng, Wang Siwei " the separation and purification research of grape pip procyanidin ", the method preparation that (grain and food industry, Vol.16,2009, No.1) reports;
The invention still further relates to a kind of pharmaceutical preparation, comprise the described lycopene and Semen Vitis viniferae compositions and pharmaceutically acceptable carrier for the treatment of effective dose;
Described carrier refers to the pharmaceutical carrier of pharmaceutical field routine, as diluent, excipient (such as water) etc., filler is as starch, sucrose, lactose, microcrystalline Cellulose etc., binding agent is as cellulose derivative, gelatin and polyvinylpyrrolidone etc., wetting agent is as glycerol etc., surfactant is as hexadecanol etc., and disintegrating agent is as calcium carbonate, crospovidone, sodium starch glycollate etc., and lubricant is as Pulvis Talci, sodium stearyl fumarate, calcium stearate and magnesium etc.
Method well known in the art can be adopted, the lycopene for the treatment of effective dose is mixed mutually with the pharmaceutically acceptable carrier of Semen Vitis viniferae compositions and one or more, be prepared into conventional solid preparation as tablet, powder, granule, capsule or injection etc.Wherein the content of active component is 0.1% ~ 99.5%(weight ratio).
Described lycopene and Semen Vitis viniferae compositions are applied to by the mode such as oral the patient needing this treatment.
For time oral, conventional solid preparation can be prepared into as tablet, powder or capsule etc.;
Amount of application of the present invention can change according to the type of the age of route of administration, patient, body weight, sex, institute's disease therapy and the order of severity etc., and its dosage is 25mg/kg-75mg/kg/ days;
The preparation method of lycopene of the present invention and Semen Vitis viniferae compositions is simple physical mixing processes, lycopene and Semen Vitis viniferae compositions is mixed.
The invention has the beneficial effects as follows:
The two component lycopenes and Semen Vitis viniferae without this kind of effect are combined by a certain percentage, makes it the effect with treatment of arthritis.Lycopene and Semen Vitis viniferae are all the active substances of efficiency natural, have no side effect to human body, non-stimulated, are compositionss safely and effectively.
Detailed description of the invention
Embodiment 1
1. zoopery
(1) animal is selected: select just ablactation Wistar rat 40 (zoopery middle school of Shenyang Pharmaceutical University provides), between body weight 80-100g.The single cage of rat is raised and is divided into 4 groups at random, often organizes 10.Animal is placed in different cages, and adapts at least one week before the experiments.Animal Lab. is equipped with automatic temperature-adjusting (22 ± 1 DEG C) and Lighting control (12 h light/12 h dark).The experimental procedure of animal and animal feeding are carried out in accordance with the system criterion of " management of laboratory animal and the service manual " of NIH.
(2) drug administration: all adopt oral administration, dosage is expressed as dosage (g)/body weight (kg)
(3) acute inflammation model: adopt the acute inflammation model of intersection dish glue induction to study the antiinflammatory action of this compositions.
Rat accepts sole of the foot rising pouring at left back foot and penetrates carrageenin (0.1ml, 1%, 0.85% saline; Sigma Chemical Co., St Louis, MO, USA).
Animal fasting 24 hours before the experiments, before injection intersects dish glue 1 hour and after 24 hours, respectively by matched group, antibiotic group and alimentation composition 1, alimentation composition 2 feeding animals, dosage and the results are shown in Table 1;
(4) assessment of foot swelling experiment
Adopt sufficient device for volume measurement (Plethysmometer7150, Ugo Basile, Italy) to measure each animal foot swelling volume (by ml), degree of accuracy is to 2 significant digits.Within 2,4,6,24 hours before and after carrageenin injection, measure.The swelling rate of pawl is sufficient percent by volume difference and by following formulae discovery: swelling rate (%)=(A-B) * 100/B, and A represents the sufficient volume of different time points after injection here, B represent injection before sufficient volume.
Result is expressed as meansigma methods ± SD.Data analysis adopts variance analysis (ANOVA), and compare between two and adopt LSD method, p<0.05 is for having significant.
(5) detection of Serum Indexes and erythrocyte sedimentation rate
(6) experimental result
Table 1 antibiotic and alimentation composition are to the effect of the rat paw edema caused by intersection dish glue
Note: * * *, p<0.001; *, p<0.01; *, p<0.05, puts at one time with matched group and compares
Compositions 1 is the mixture of lycopene and Semen Vitis viniferae extract, and the weight ratio of lycopene and Semen Vitis viniferae extract is 1:3;
Compositions 2 is the mixture of lycopene and Semen Vitis viniferae extract, and the weight ratio of lycopene and Semen Vitis viniferae extract is 1:3;
Table 2 on Serum Indexes and erythrocyte sedimentation rate impact (mm/h,
)
*: P < 0.05 compared with matched group,
Compositions 1 is the mixture of lycopene and Semen Vitis viniferae extract, and the weight ratio of lycopene and Semen Vitis viniferae extract is 1:3;
Compositions 2 is the mixture of lycopene and Semen Vitis viniferae extract, and the weight ratio of lycopene and Semen Vitis viniferae extract is 1:3;
Compared with matched group, to TNF, T-SOD, BSR, there were significant differences, compared with antibiotic for compositions
Without significant difference and compositions suitable with the effect of antibiotic group.
Known by table 1, table 2, antibiotic group and compositions 2 pairs of erythrocyte sedimentation rate effects obviously, have clear improvement to Serum Indexes.
2. clinical research
(1) clinical subjects: test group 75 example, wherein male 30 example, women 45 example, oldest 78 years old, minimum 51 years old, average 60.82 years old, the course of disease was the longest 20 years, the shortest 1 year, average 4.03 years.Matched group 75 example, wherein male 35 example, women 40 example, the oldest 78 years old, minimum 50 years old, average 59.59 years old, the course of disease was the longest 18 years, the shortest 6 months, average 3.35 years.Through statistical procedures P>0.05, both explanations without significant difference, have comparability in sex, age, the course of disease.
(2) Therapeutic Method: matched group diclofenac sodium enteric-coated tablets; The oral present composition of test group; Dosage: every day 2 times, each 2, the heavy 775mg of every sheet; 28 days cycles;
Described invention compositions, its component is:
Formula: (weight)
(3) observation of curative effect:
Clinical symptoms: arthralgia, articular pain, arthroncus, joint motion;
(4) experimental result
Clinicing symptom observation
Compared with matched group, test group is without significant difference, and two groups of effects are suitable.In long-term efficacy investigation subsequently, test group patient do not recur substantially.
Embodiment 2
Formula: (weight)
Adopt method well known in the art, after said components being mixed, carry out tabletting, obtain the heavy 800mg of the every sheet of tablet.
Adopt the method that embodiment 1 is identical, test,
Clinical symptoms: arthralgia, articular pain, arthroncus, joint motion;
Experimental result
Clinicing symptom observation:
Compared with matched group, test group is without significant difference, and two groups of effects are suitable.In long-term efficacy investigation subsequently, test group patient do not recur substantially.
Claims (6)
1. lycopene and Semen Vitis viniferae compositions are preparing the application in medicament for treating arthritis.
2. application according to claim 1, is characterized in that, the weight ratio of lycopene and Semen Vitis viniferae extract is: lycopene: Semen Vitis viniferae extract=1: 1 ~ 10.
3. application according to claim 1, is characterized in that, the weight ratio of lycopene and Semen Vitis viniferae extract is: lycopene: Semen Vitis viniferae extract=1: 2 ~ 5.
4. application according to claim 1, is characterized in that, the weight ratio of lycopene and Semen Vitis viniferae extract is: lycopene: Semen Vitis viniferae extract=1: 2 ~ 3.
5. a pharmaceutical preparation, is characterized in that, comprises the described lycopene and Semen Vitis viniferae compositions and pharmaceutically acceptable carrier for the treatment of effective dose.
6. pharmaceutical preparation according to claim 5, is characterized in that, described preparation is tablet, powder, granule, capsule or injection.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310733246.5A CN104740112A (en) | 2013-12-26 | 2013-12-26 | Application of composition of lycopene and grape seed in preparation of drug used for treating arthritis |
| CN202010290228.4A CN111265599A (en) | 2013-12-26 | 2013-12-26 | Application of lycopene and grape seed composition in preparation of medicine for treating arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310733246.5A CN104740112A (en) | 2013-12-26 | 2013-12-26 | Application of composition of lycopene and grape seed in preparation of drug used for treating arthritis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010290228.4A Division CN111265599A (en) | 2013-12-26 | 2013-12-26 | Application of lycopene and grape seed composition in preparation of medicine for treating arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104740112A true CN104740112A (en) | 2015-07-01 |
Family
ID=53580734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310733246.5A Pending CN104740112A (en) | 2013-12-26 | 2013-12-26 | Application of composition of lycopene and grape seed in preparation of drug used for treating arthritis |
| CN202010290228.4A Pending CN111265599A (en) | 2013-12-26 | 2013-12-26 | Application of lycopene and grape seed composition in preparation of medicine for treating arthritis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010290228.4A Pending CN111265599A (en) | 2013-12-26 | 2013-12-26 | Application of lycopene and grape seed composition in preparation of medicine for treating arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN104740112A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106860694A (en) * | 2017-03-10 | 2017-06-20 | 上海博宣健康科技有限公司 | Treatment gastric dynamic dysfunction contains the composition of lycopene and grape seed extract |
| CN106937987A (en) * | 2016-01-04 | 2017-07-11 | 上海宣泰生物科技有限公司 | Self-emulsifying eicosapentaenoic acid nutrient composition and its application |
| CN108785414A (en) * | 2018-08-17 | 2018-11-13 | 上海宣泰生物科技有限公司 | Improve composition and its application of osteoarthritic inflammation |
| CN112043822A (en) * | 2020-09-25 | 2020-12-08 | 福建省春秋刺明珠葡萄酒庄园有限公司 | Vitis davidii plant extract preparation rich in anthocyanin and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230015A (en) * | 2013-05-20 | 2013-08-07 | 李铁清 | Extract compound for delaying senility, improving immunity and preventing and resisting cancer |
-
2013
- 2013-12-26 CN CN201310733246.5A patent/CN104740112A/en active Pending
- 2013-12-26 CN CN202010290228.4A patent/CN111265599A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230015A (en) * | 2013-05-20 | 2013-08-07 | 李铁清 | Extract compound for delaying senility, improving immunity and preventing and resisting cancer |
Non-Patent Citations (3)
| Title |
|---|
| G.L RENJU.ET AL.: "Anti-inflammatory activity of lycopene isolated from Chlorella marina on Type II Collagen induced arthritis in Sprague Dawley rats", 《IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY》 * |
| JIN-SIL PARK.ET AL.: "Grape-Seed Proanthocyanidin Extract as Suppressors of Bone Destruction in Inflammatory Autoimmune Arthritis", 《PLOS ONE》 * |
| 唐春红: "《天然防腐剂与抗氧化剂》", 31 May 2010, 中国轻工业出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106937987A (en) * | 2016-01-04 | 2017-07-11 | 上海宣泰生物科技有限公司 | Self-emulsifying eicosapentaenoic acid nutrient composition and its application |
| CN106860694A (en) * | 2017-03-10 | 2017-06-20 | 上海博宣健康科技有限公司 | Treatment gastric dynamic dysfunction contains the composition of lycopene and grape seed extract |
| CN108785414A (en) * | 2018-08-17 | 2018-11-13 | 上海宣泰生物科技有限公司 | Improve composition and its application of osteoarthritic inflammation |
| CN112043822A (en) * | 2020-09-25 | 2020-12-08 | 福建省春秋刺明珠葡萄酒庄园有限公司 | Vitis davidii plant extract preparation rich in anthocyanin and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111265599A (en) | 2020-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101491572A (en) | Medicine for treating calculus and preparation method thereof | |
| CN104740112A (en) | Application of composition of lycopene and grape seed in preparation of drug used for treating arthritis | |
| CN102379941B (en) | A kind of compound Chinese medicinal preparation treating fracture and preparation method thereof | |
| CN102406900B (en) | External traditional Chinese preparation for treating hyperplasia of mammary glands | |
| CN104127776A (en) | Traditional Chinese medicine for treating ancylostomiasis | |
| CN106937987A (en) | Self-emulsifying eicosapentaenoic acid nutrient composition and its application | |
| CN101019941A (en) | Chinese medicine prepn for treating osteochondrosis of tibial tubercle and other diseases | |
| CN107260780B (en) | Traditional Chinese medicine composition for treating rheumatic arthritis | |
| CN102716381B (en) | Traditional Chinese medicine used for treating appendicitis | |
| WO2016127771A1 (en) | Application of 20(r)-ginsenoside rg3 in preparing drug or healthcare product for alleviating or/and treating rheumatoid disease and drug containing 20(r)-ginsenoside rg3 | |
| CN102846750B (en) | Fengtongning composite preparation and preparation method thereof | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN106540119B (en) | Its pharmaceutical composition of compound wood Ni Zi is preparing the purposes in analgesic | |
| CN104189336B (en) | A kind of pharmaceutical composition for the treatment of hyperosteogeny | |
| CN102512652B (en) | Medicinal composition for treating peptic ulcer | |
| CN102671076B (en) | Medicament for treating gout | |
| CN108785414A (en) | Improve composition and its application of osteoarthritic inflammation | |
| CN102225125B (en) | Externally applied traditional Chinese medicine composite for treating joint pain caused by rheumatoid arthritis and preparation method thereof | |
| CN101612263B (en) | Traditional Chinese medicine preparation for treating acute and chronic gastroenteritis | |
| CN106266705A (en) | A kind of pharmaceutical composition treating gout | |
| WO2023284426A1 (en) | Anti-gout celery seed-flos sophorae immaturus extract and febuxostat pharmaceutical composition, and use thereof | |
| CN107233430B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN107233410B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| KR20170136213A (en) | Chinese medicine composition | |
| TWI262793B (en) | Composition for the treatment of systemic lupus erythematosus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151224 Address after: 201210 Shanghai Haike road Zhangjiang High Tech Park No. 99, No. 3 Building 1 floor Applicant after: Shanghai Xuantai Pharmaceutical Technology Co., Ltd. Address before: 201210 Shanghai Zhangjiang hi tech Park No. 780 Cailun Road, 5 floor M block Applicant before: Xuan Tai bio tech ltd, Shanghai |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150701 |